STOCK TITAN
  1. Home
  2. News
  3. LEGN

Legend Biotech Corp - LEGN STOCK NEWS

Welcome to our dedicated news page for Legend Biotech (Ticker: LEGN), a resource for investors and traders seeking the latest updates and insights on Legend Biotech.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Legend Biotech's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Legend Biotech's position in the market.

News
Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results
Rhea-AI Summary
Legend Biotech (LEGN) will host a conference call to review first-quarter 2024 results. Senior leaders will provide an overview of the company's performance. Investors can join the live webcast and access a replay version later.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.87%
Tags
conferences earnings
-
News
Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
Rhea-AI Summary
Legend Biotech's CARVYKTI® receives FDA approval for treating relapsed or refractory multiple myeloma, offering a new treatment option with improved progression-free survival. The therapy targets B-cell Maturation Antigen, providing hope for patients and physicians.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
none
-
News
Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report
Rhea-AI Summary
Legend Biotech (NASDAQ: LEGN) releases its inaugural Environmental, Social & Governance (ESG) report, showcasing commitment to patients, employees, and communities. Key pillars include patient care, innovation, employee engagement, community involvement, operational efficiency, and integrity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.85%
Tags
none
News
CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma
Rhea-AI Summary
Legend Biotech's CARVYKTI Receives Positive FDA ODAC Vote for Multiple Myeloma Treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.16%
Tags
none
-
News
Legend Biotech Reports Fourth Quarter and Full Year 2023 Results and Recent Highlights
Rhea-AI Summary
Legend Biotech (LEGN) reports net trade sales of $159 million for Q4 2023 and $500 million for the full year. FDA to review data for CARVYKTI® label expansion. Legend received $100 million upfront payment from Novartis. Financially, they have $1.3 billion in cash and equivalents.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.07%
Tags
earnings
-
News
Legend Biotech Announces Positive CHMP Opinion for CARVYKTI® (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of Therapy
Rhea-AI Summary
Legend Biotech's CARVYKTI® receives positive CHMP opinion for expanded label in treating relapsed and refractory multiple myeloma patients, supported by CARTITUDE-4 study results. The therapy aims to provide innovative treatment options to patients in Europe.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.1%
Tags
none
News
Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2023 Results
Rhea-AI Summary
Legend Biotech Corporation (LEGN) will host a conference call to review fourth-quarter and full-year 2023 results. Executive members will discuss the company's performance during the call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.99%
Tags
conferences earnings
-
News
Legend Biotech Announces Closing of License Transaction for Certain CAR-T Therapies Targeting DLL3
Rhea-AI Summary
Legend Biotech Corporation (LEGN) has closed an exclusive worldwide license agreement with Novartis Pharma AG for certain Legend Biotech chimeric antigen receptor T-cell (CAR-T) cell therapies targeting Delta-like ligand protein 3 (DLL3), including Legend Biotech’s existing autologous CAR-T cell therapy candidate, LB2102 (NCT05680922). Under the terms of the agreement, Legend Biotech will receive a $100 million upfront cash payment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.98%
Tags
none
-
News
Legend Biotech to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Legend Biotech Corporation (NASDAQ: LEGN) will participate in the 42nd annual J.P. Morgan Healthcare Conference. Ying Huang, Ph.D., the company’s CEO, will deliver the presentation on Tuesday, January 9, 2024, at 2:15 p.m. PT. The live audio webcast will be available on Legend’s website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.78%
Tags
conferences
News
Patient-Reported Outcomes from the CARTITUDE-4 Study Showed Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Multiple Myeloma Symptoms Following Treatment with CARVYKTI® (ciltacabtagene autoleucel)
Rhea-AI Summary
Legend Biotech Corporation (NASDAQ: LEGN) announced that patient-reported outcome (PRO) data from the Phase 3 CARTITUDE-4 study showed clinically meaningful improvement in health-related quality of life following a single CARVYKTI® infusion in adults lenalidomide-refractory multiple myeloma (MM) patients. The as-treated population in CARTITUDE-4 demonstrated strong rates of progression-free survival and overall response. Longer-term data from CARTITUDE-2 showed deep and durable responses in earlier lines of treatment among patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.57%
Tags
none
Stock LEGN logo
Legend Biotech Corp

Nasdaq:LEGN

LEGN Rankings

#837 Ranked by Market Cap
#704 Ranked by Stock Gains
N/A Ranked by Dividends

LEGN Stock Data

9.63B
158.77M
1.32%
48.72%
5.49%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Somerset

About LEGN

legend biotech corporation is an emerging company focusing on the development of the best-in-class immunotherapy technology for cancer cure. teamed up with outstanding immunologists and molecular biologists, legend has generated a strong pipeline of chimeric antigen receptor(car) product candidates to treat a wide variety of liquid and solid tumors. our ambition to succeed in the cars field has been substantially fulfilled by the latest clinical trial results that we have achieved a great clinical success in treating multiple myeloma, a previously incurable blood cancer. by applying one of our proprietary car-t technology, we have reached a promising result in the clinical research for the enrolled patient group bearing refractory and relapsed multiple myeloma. legend biotech corporation is founded on the vision that the previous incurable previousincurable cancer will be safely and effectively treated with fine-tuning products generated on our innovative technology platform. we take o